Duration of Vascular Endothelial Growth Factor Suppression after Intravitreal Injection of Faricimab in Macaque Eyes.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2024-10-02 DOI:10.1089/jop.2024.0138

Riko Matsumoto, Shumpei Obata, Masashi Kakinoki, Osamu Sawada, Ikuo Kawamoto, Mitsuru Murase, Masahito Ohji

{"title":"Duration of Vascular Endothelial Growth Factor Suppression after Intravitreal Injection of Faricimab in Macaque Eyes.","authors":"Riko Matsumoto, Shumpei Obata, Masashi Kakinoki, Osamu Sawada, Ikuo Kawamoto, Mitsuru Murase, Masahito Ohji","doi":"10.1089/jop.2024.0138","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the duration of vascular endothelial growth factor (VEGF) suppression in the aqueous humor of macaque eyes after intravitreal faricimab (IVF) injection. Methods: Faricimab (6 mg/50 µL) was injected into the vitreous cavity of the right eye of 6 macaques. Aqueous humor samples (150 μL) were collected from both eyes immediately before injection and on days 1, 3, 7, 14, 21, 28, 42, 56, 84, and 112 after injection. The VEGF concentrations in the aqueous humor were measured using an enzyme-linked immunosorbent assay. Results: The VEGF was undetectable until 4 weeks after IVF injection in 4 eyes and until 6 weeks in the remaining 2 eyes. The mean duration of complete VEGF suppression was 4.7 weeks (range, 4-6 weeks). The VEGF concentration did not decrease in the aqueous humor of the non-injected fellow eyes. Conclusions: Faricimab effectively suppressed the VEGF concentrations in the aqueous humor of macaques for an average of 4.7 weeks after a single intravitreal injection. It did not reduce the VEGF concentrations in the aqueous humor of the fellow eyes.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ocular Pharmacology and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jop.2024.0138","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the duration of vascular endothelial growth factor (VEGF) suppression in the aqueous humor of macaque eyes after intravitreal faricimab (IVF) injection. Methods: Faricimab (6 mg/50 µL) was injected into the vitreous cavity of the right eye of 6 macaques. Aqueous humor samples (150 μL) were collected from both eyes immediately before injection and on days 1, 3, 7, 14, 21, 28, 42, 56, 84, and 112 after injection. The VEGF concentrations in the aqueous humor were measured using an enzyme-linked immunosorbent assay. Results: The VEGF was undetectable until 4 weeks after IVF injection in 4 eyes and until 6 weeks in the remaining 2 eyes. The mean duration of complete VEGF suppression was 4.7 weeks (range, 4-6 weeks). The VEGF concentration did not decrease in the aqueous humor of the non-injected fellow eyes. Conclusions: Faricimab effectively suppressed the VEGF concentrations in the aqueous humor of macaques for an average of 4.7 weeks after a single intravitreal injection. It did not reduce the VEGF concentrations in the aqueous humor of the fellow eyes.

查看原文本刊更多论文

在猕猴眼中静脉注射法利西单抗后血管内皮生长因子抑制的持续时间。

目的：评估玻璃体内注射法尼单抗（IVF）后猕猴眼房水中血管内皮生长因子（VEGF）抑制的持续时间。研究方法向 6 只猕猴右眼玻璃体腔内注射法利单抗（6 mg/50 µL）。在注射前和注射后的第 1、3、7、14、21、28、42、56、84 和 112 天，采集双眼的眼房水样本（150 μL）。使用酶联免疫吸附法测定房水中的血管内皮生长因子浓度。结果显示4 只眼睛在注射 IVF 后 4 周内检测不到血管内皮生长因子，其余 2 只眼睛在注射 IVF 后 6 周内检测不到血管内皮生长因子。血管内皮生长因子完全抑制的平均持续时间为 4.7 周（范围为 4-6 周）。未注射 IVF 的同侧眼房水中的 VEGF 浓度并未下降。结论法利西单抗在一次玻璃体内注射后，能有效抑制猕猴眼房水中的血管内皮生长因子浓度，平均持续4.7周。它并没有降低同组眼睛眼房水中的血管内皮生长因子浓度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ocular Pharmacology and Therapeutics 医学-眼科学

CiteScore

4.60

自引率

4.30%

发文量

审稿时长

1 months

期刊介绍： Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.